4DX4dmedical

4DMedical shares rose sharply following a new securities quotation application, likely reflecting a capital raise or option conversion bringing fresh investor attention alongside positive media coverage of its lung imaging technology and strong one-year price momentum.

4DMedical shares fell sharply amid a multi-day pattern of selling and investor risk reassessment, with no specific company announcement to explain the move, suggesting profit-taking or sentiment deterioration following recent volatility

Broad positive investor sentiment returned to ASX healthcare and health-tech stocks, with 4DMedical being highlighted as a red-hot climber without a specific company announcement.

4DMedical shares surged following a major US imaging network deal announced on May 29, 2026.

4DMedical shares dropped 10.14% on May 20, 2026, likely due to profit-taking and a broad market slide to a seven-week low driven by an oil shock and bond sell-off.

4DMedical shares rose 13.31% on May 14, 2026, likely driven by a broader investor rush into healthcare imaging stocks, as indicated by headlines about volatile trading and investor interest.

The stock moved down likely due to broad small-cap biotech sector sentiment, as evidenced by article about Cynata Therapeutics and overall small-cap biotech flows.

4DMedical received CE Mark approval for its CT:VQ imaging technology and entered a partnership with the Mayo Clinic, driving a 34% surge.

4DMedical completed a $150 million institutional placement, driving investor interest and a sharp share price rise despite the dilutive nature of the raise.

4DMedical announced UC San Diego Health as the 4th US academic user and commercial adopter of its CT:VQ pulmonary imaging technology.

4DMedical surged on a material partnership deal with the Cleveland Clinic for its CT:VQ technology, following a Canadian regulatory approval announcement.

4DMedical shares surged following Canadian regulatory approval and an expanded distribution deal with Philips.